MASH / metabolic liver disease
Pemvidutide vs Survodutide
Both GLP-1/glucagon dual agonists have biopsy-based MASH data; compare endpoints carefully because study populations, fibrosis stages, doses and timepoints.
At a glance
Pemvidutide
Survodutide
Human evidence
Phase 2 obesity research showed substantial weight loss, while randomized MASLD/MASH trials demonstrated large liver-fat reductions and MASH-resolution signals. A global Phase 3 MASH programme began in 2026.
Randomized Phase 2 studies show dose-dependent weight loss in obesity and histologic MASH improvement without fibrosis worsening. Phase 3 development is ongoing.
Research focus
Obesity, MASLD, MASH, alcohol-related liver disease, cardiometabolic risk
Obesity, MASH, liver fibrosis, cardiovascular outcomes
Regulatory status
Investigational. FDA granted Breakthrough Therapy Designation for MASH based on early clinical evidence; this is not marketing approval.
Investigational; no general marketing authorisation for obesity or MASH identified in the reviewed jurisdictions.
Route / formulation
Trial-grade once-weekly subcutaneous product; Breakthrough Therapy designation must not be presented as FDA approval.
Evidence is from trial-grade once-weekly subcutaneous product with protocol-driven escalation.
No direct head-to-head trial identified Both GLP-1/glucagon dual agonists have biopsy-based MASH data; compare endpoints carefully because study populations, fibrosis stages, doses and timepoints differ.